Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Yaogang ZhongCenter for Cancer Metabolism, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Liqing HeDepartment of Chemistry, Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, USA.
Xinmin YinDepartment of Chemistry, Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, USA.
Logan MazikCenter for Cancer Metabolism, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Xiang ZhangDepartment of Chemistry, Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, USA.
Deliang GuoCenter for Cancer Metabolism, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Funding
Determining the role of lipid droplets in glioblastoma and their therapeutic potentialR01NS104332 · NINDS · OHIO STATE UNIVERSITY · PI Deliang Guo · 2018 to 2026
$4.2M
Delineating how retinoic acids regulate lipid metabolism in glioblastoma and their resistance mechanismsR01CA240726 · NCI · OHIO STATE UNIVERSITY · PI GUO, DELIANG · 2020 to 2024
$2.2M
Identifying SREBP-1 activation mechanism in glioblastoma and its new role in regulating glutamine metabolismR01NS112935 · NINDS · OHIO STATE UNIVERSITY · PI GUO, DELIANG · 2020 to 2024
$1.8M
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastomaR01CA227874 · NCI · OHIO STATE UNIVERSITY · PI CHAKRAVARTI, ARNAB, GUO, DELIANG · 2019 to 2023
$1.5M
Novel lipid and glutamine metabolism-based combination therapies for glioblastomaR01NS141312 · NINDS · OHIO STATE UNIVERSITY · PI Deliang Guo · 2025 to 2026
Stable isotopes have frequently been used to study metabolic processes in live cells both in vitro and in vivo. Glutamine, the most abundant amino acid in human blood, plays multiple roles in cellular metabolism by contributing to the production of nucleotides, lipids, glutathione, and other amino acids. It also supports energy production via anaplerosis of tricarboxylic acid cycle intermediates. While
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.